This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Intra-Cellular Surges on Optimistic Outlook for Schizophrenia Drug

Schizophrenia patients treated with an experimental drug from Intra-Cellular Therapies reported fewer antipsychotic symptoms compared to a placebo in a large, phase III study, the company said Wednesday.

Amgen Adds Cholesterol-Lowering Pill to Pipeline With New Acquisition

Amgen is acquiring a privately held company developing a cholesterol-lowering pill just weeks after receiving approval for its own cholesterol-lowering injection.

Diarrhea Dings Xenoport Psoriasis Drug Study Results

An experimental pill from Xenoport reduced psoriasis skin symptoms significantly more than a placebo in a mid-stage study, but a high rate of diarrhea raises questions about the drug's future.

Tetraphase Executive Profits Hours Before Stock Plummets

A Tetraphase insider executed a well-timed insider stock sale right before the company's share price fell on negative clinical trial results.

Is FDA Having Trouble Setting Date for Biomarin, Sarepta Advisory Panels?

FDA missed a deadline earlier this week to finalize the Biomarin/Sarepta advisory panels on Nov. 23-24, if (and only if) Nov. 23-24 were the chosen dates.

Spark Tries to Quell Investor Fears About Gene Therapy Test

Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.

Biogen Takes on Celgene With New Autoimmune License Deal

Biogen stepped into the oral S1P modulator race Wednesday with the acquisition of a license to develop a mid-stage compound from Japan's Mitsubishi Tanabe Pharma.

Santhera Drug Wins European Approval for Rare Blindness Disease

The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients in Europe.

Tuesday's Clinical Trial Scorecard: Akebia Wins, Tetraphase, Flexion, Theravance Lose

Four biotech companies announced important clinical trials results Tuesday at market close.

Global Blood Valuation Gives Goldman Analyst Pause

Sell-side cheerleading on behalf of their employer's banking clients has become such a standard practice that anything remotely bearish is news.

Page 2 of 342
Top Rated Stocks Top Rated Funds Top Rated ETFs